FDA Acceptance of Libervant™ (diazepam) Buccal Film NDA for treatment of seizure clusters in patients between two and five years...
New assays for ketamine and tramadol testing pass initial Intelligent Fingerprinting design phase and begin next stage of transfer to...
Published Phase 2 Study findings demonstrate safety and efficacy of idrevloride in hypertonic saline for treatment of primary ciliary dyskinesiaAbstract...
--Site activation allows for patients in the State of New York to participate in the BRTX-100 trial— --15 Clinical Sites...
BERKELEY HEIGHTS, N.J., Sept. 08, 2023 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and...
Episode to be Broadcast on Monday, September 11th and Tuesday, September 19th 2023 at 7:30 a.m. (ET/PT) TORONTO, Sept. 08,...
Two best-in-class lung imaging companies combine expertise for the deployment of a new xenon 129 MRI platform.Durham, NC and London,...
BOSTON, Sept. 08, 2023 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the...
Marijuana DeScheduling News Much To Do Over NothingWASHINGTON D.C. / ACCESSWIRE / September 8, 2023 / Attorney Megan Sheehan representing...
San Diego, California--(Newsfile Corp. - September 7, 2023) - Skye Bioscience, Inc. (OTCQB: SKYE) ("Skye"), a pharmaceutical company developing proprietary...
HumanFirst's new solution aligns AI-powered biomarkers and clinical outcome assessments (COAs) across one platform to drive scientific progress, R&D efficiencies,...
NEW YORK, Sept. 7, 2023 /PRNewswire/ -- New York Cancer & Blood Specialists (NYCBS), one of the nation's leading oncology...
BEIJING, Sept. 7, 2023 /PRNewswire/ -- Waterdrop Inc. ("Waterdrop", the "Company" or "we") (NYSE: WDH), a leading technology platform dedicated to...
Completion of enrollment of study on track by end of 2023Topline data results from interim analysis also on track to...
Jaguar is supporting investigator-initiated proof-of-concept studies of crofelemer for the rare disease indications of short bowel syndrome and microvillus inclusion...
Investigational New Drug (IND) application submitted to U.S. Food and Drug Administration (FDA) for ELX-02 for the treatment of Alport...
Five upcoming scientific presentations will add to the body of evidence supporting the advancement of LX9211 into late-stage development Phase...
Table 1 Table 1 Chart 1 Chart 1 Chart 2 Chart 2 Table 2 Table 2All study objectives were met,...
SAN DIEGO, Sept. 07, 2023 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the...
ESCRS presentations will feature clinical data on APX3330 in diabetic retinopathy; Nyxol® data in presbyopia, dim light vision disturbance and...